Rheumatology Network Newsletter

To view this email as a web page, click here.

First-Ever Treatment for Lupus Nephritis Wins FDA Approval

Roche announced this week that the U.S. Food and Drug Administration granted breakthrough therapy designation of obinutuzumab (Gazyva) for lupus nephritis, a major morbidity of systemic lupus erythematosus (SLE).

Our Picks for the Top 9 Lupus Nephritis Studies that Should be on Your Radar

Investigators are currently pursuing at least 50 possible new treatments, or treatment targets, for systemic lupus and lupus nephritis. We're tracking the studies and in this slideshow, we highlight the results from nine new studies on lupus nephritis.

Nephritis Sets in Early in Lupus, Treatment Guidelines Can Stave Off Worsening Condition

By the time a patient is diagnosed with systemic lupus erythematosus, nephritis has already set in for approximately 35 percent of patients. And, wit hin 10 years, the number climbs to 50-60 percent of patients. The very presence of lupus nephritis reduces survival from 92 percent at 10 years to 88 percent, according to one estimate. The American College of Rheumatology offers screening, treatment and management guidelines for lupus nephritis patients. In this slideshow, we review the options.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.